Revised CDAP In Effect — Additional Medications Added

The Ministry of Health has announced the implementation of the revised Chronic Disease Assistance Programme (CDAP), effective from 1st October, 2025. The announcement comes approximately four (4) months after a comprehensive review was commissioned by Minister of Health, Dr. Lackram Bodoe, on 5th June, 2025, as part of the Government’s Health Reform Programme. 

The CDAP Review Committee, which was tasked with assessing the programme’s clinical, operational, and financial performance, found that while CDAP remains a crucial public good, its drug list must be updated, its diagnostics strengthened, and its structure modernized to reflect the current medical realities.

The revised CDAP now allows more than 300,000 citizens to access updated and better quality of drugs for chronic diseases. 

Additional medications available under the revised programme include the following:

1. Losartan Potassium 50mg tablets; 
2. Clopidogrel Bisulphate 75mg tablets;
3. Risperidone 2mg tablets;
4. Sertraline 50mg tablets; and 
5. Rosuvastatin 20mg tablets.

Minister Bodoe, on commenting on the availability of new medication under the revised CDAP, stated, “The review of CDAP not only ensures safer and more effective medicines for more than 300,000 citizens, but greater access particularly in rural communities, stronger diagnostics, and cost in savings, all aimed at delivering higher quality care and greater value for the people of Trinidad and Tobago.”

The Ministry said it remains committed to protecting the health and wellbeing of the national population.

More on this as it becomes available.